Combination of Focused Ultrasound, Immunotherapy, and Chemotherapy: New Perspectives in Breast Cancer Therapy
- PMID: 35869903
- DOI: 10.1002/jum.16053
Combination of Focused Ultrasound, Immunotherapy, and Chemotherapy: New Perspectives in Breast Cancer Therapy
Abstract
Focused ultrasound is a treatment modality increasingly used for diverse therapeutic applications, and currently approved for several indications, including prostate cancers and uterine fibroids. But what about breast cancer? Breast cancer is the most common and deadliest cancer in women worldwide. While there are different treatment strategies available, there is a need for development of more effective and personalized modalities, with fewer side effects. Therapeutic ultrasound is such an option, and this review summarizes the state of the art in their use for the treatment of breast cancer and evaluate potentials of novel treatment approaches combining therapeutic ultrasound, immuno- and chemo-therapies.
Keywords: breast cancer; chemotherapy; high intensity focused ultrasound (HIFU); immunotherapy; targeted therapy; therapeutic ultrasound.
© 2022 The Authors. Journal of Ultrasound in Medicine published by Wiley Periodicals LLC on behalf of American Institute of Ultrasound in Medicine.
References
REFERENCES
-
- World Health Organization. Breast Cancer [Internet]. Geneva, Switzerland: World Health Organization. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/breast-cancer
-
- Ferreira AR, Di Meglio A, Pistilli B, et al. Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. Ann Oncol [Internet]. 2019;30:1784-1795. Available from: https://doi.org/10.1093/annonc/mdz298
-
- Izadifar Z, Izadifar Z, Chapman D, Babyn P. An introduction to high intensity focused ultrasound: systematic review on principles, devices, and clinical applications. J Clin Med 2020; 9:1-22.
-
- National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and management [Internet]. NICE Guideline No.101. 2018. Available from: https://www.nice.org.uk/guidance/ng101
-
- von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab Emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380:617-628.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical